iowave |
||||||
|
News for 14-Dec-25 Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet High Blood Pressure General Source: MedicineNet High Blood Pressure General Source: MedicineNet High Blood Pressure General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General
|
The Best iowave websiteAll the iowave information you need to know about is right
here. Presented and researched by http://www.mdnewscast.net. We've searched
the information super highway far and wide to provide you with the
best iowave site on the internet today. The links below will
assist you in your efforts to find the information that you are looking
for about
iowave
Hints and tips when you are searching for iowave. Well the first thing to do is type in the exact phrase that you are looking for, but I guess that you already know that seeing that you've just searched for iowave and this web page came up. The biggest tip that I've got is not to bother looking any further. You have already struck the Eldorado of iowave information. The leaders of the pack. The holy grail of Internet info on the sometimes not so easy to find subject of iowave. That's not to say you're at that page right now, because our iowave site is too new to be the best in the field, or even in the top 10 websites. But the Internet sites that we link to above are the leaders of the pack. iowave
Everything you wanted to know about iowaveSo you’re looking for valuable information about iowave, well you’ve come to the right place. Although our site may not contain all the information you may be looking for on iowave I think you’ll find the links below will provide more than enough information. Our team of internet market researcher’s have spent months researching iowave for you and have come up with the best sites available on the net to date. So why wait? click on the links above to find out all about iowave. The internet is growing at an enormous rate these days and all the information on iowave that’s out there can take a long time to sift through. It took a long time, and a lot of hard work, for us to go through every information source about iowave and pick out just a couple of the very best sites for you to visit. We trust that you'll find our judgement sound. Like you we're very interested in iowave, which is why we wrote this page about it. Right now I guess you should click on one of the links or zoom straight to the iowave site that probably popped up when you entered this page. Thanks for visiting here. Drug Offers Hope to Cancer Patients by: ARA Content
(ARA) - A decade ago, research into angiogenesis-inhibiting compounds was still in a relative state of infancy. The principle itself was not new -- as far back as the early '70s, there was speculation that human cancer tumors could not grow beyond a few millimeters in diameter without obtaining their own blood supply. But opinion was still divided in the scientific community. Angiogenesis itself is a natural and necessary physiological function, which refers to the process by which new blood vessels form and develop. In its pathological form, however, angiogenesis is also implicated in the progression of more than 20 different diseases, including cancer. In order to grow, solid tumors need to be supplied by blood vessels that act as conduits for oxygen and nutrients. Once a vascular network has been generated around a tumor, cancerous cells can then invade the rest of the body, a process called metastasis. Angiogenesis inhibitors block the formation of new blood vessels, without which cancerous cells are starved and tumors cannot grow. In recent years, the therapeutic potential of angiogenesis inhibitors has gained wide acceptance. Indeed, the scientific community now believes that more than 90 percent of all cancer cases are angiogenesis dependent. The industry spends nearly $4 billion annually in angiogenic research and more than 100 research organizations and companies are currently developing angiogenesis-blocking drugs. Æterna Laboratories Inc. is at the forefront of this effort. In fact, it is one of the very few biotechnology companies in the world with an angiogenesis-blocker in Phase lll clinical development. Its proprietary compound, Neovastat, is currently the subject of Phase III trials in lung and kidney cancer and a Phase ll trial in multiple myeloma, a form of blood cancer. Neovastat possesses multiple mechanisms of action that counteract the angiogenic process. Among competing products, this makes it unique. It has also shown an excellent safety profile in clinical trials. Further advantages of Neovastat are that it is orally administered, which makes it convenient for patients who must receive treatment on a long-term basis, and it may be taken in association with standard therapies such as chemotherapy. Angiogenesis blockers are not a cure for cancer. They are a form of treatment -- in the same way that insulin is a treatment for diabetes -- that should allow patients to lead a more normal life, without suffering from the often debilitating side-effects that some treatments can produce. Æterna's clinical trials strategy has targeted forms of cancer for which there is an urgent need for new therapies. Since 1996, Neovastat has been tested in more than 850 patients in North American and European countries. Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer. For multiple myeloma, the second most common form of blood cancer, the drug is in Phase II trials with 125 patients in the United States, Canada and Europe. This trial should be completed in early 2003. For progressive renal cell carcinoma, the drug is in Phase III trials with 302 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a Phase III trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005. Once the clinical trials are complete, health authorities in various countries can then assess these results and make decisions on approval.
|
|||||
|
http://www.medmeet.com/ |
||||||
| MD Meet Take Medicine Correctly Take Your Meds |